{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:51:29Z","timestamp":1760143889495,"version":"build-2065373602"},"reference-count":14,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: In Canada, individuals with gynecologic reproductive organs (ovaries, fallopian tubes, uterus) over the age of 70 comprise a large proportion of epithelial ovarian cancer patients. These patients often have co-morbidities, polypharmacy, or decreased functional status that may impact treatment initiation and tolerance. Despite this, there is limited evidence to guide treatment for older patients diagnosed with ovarian epithelial carcinoma. Methods: This is a retrospective study with data from Manitoba, Canada. The data were obtained from the Manitoba Ovarian Cancer Database, the Manitoba Cancer Registry, and electronic health records. All individuals with epithelial ovarian, fallopian tube, or peritoneal cancer diagnosed between 2009 and 2018 were identified. Patients aged &gt; 70 at the time of diagnosis were included in the study cohort. Results: Four hundred and forty individuals were included. The majority had advanced stage disease (56%). Moreover, 59% of patients received no chemotherapy. Of the patients who received chemotherapy, 20% received &lt;2 cycles and 21% required a dose reduction due to toxicity. Univariable and multivariable analysis identified advanced stage (p &lt; 0.001), treatment modality (p &lt; 0.001), and advanced age at diagnosis (p &lt; 0.001) with poorer overall survival. Conclusions: Our study demonstrated a high rate of chemotherapy dose reduction and discontinuation in the elderly epithelial ovarian cancer population. Further research is needed to identify risk factors for treatment discontinuation and intolerance in this population.<\/jats:p>","DOI":"10.3390\/curroncol31030102","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T05:31:19Z","timestamp":1709616679000},"page":"1348-1358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ovarian Cancer in the Older Manitoban Population\u2014Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0555","authenticated-orcid":false,"given":"Lesley F.","family":"Roberts","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3E 0L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"},{"name":"Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3291-8628","authenticated-orcid":false,"given":"Mark W.","family":"Nachtigal","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3E 0L8, Canada"},{"name":"Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"},{"name":"Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB R3E 0J9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-4910","authenticated-orcid":false,"given":"Alon D.","family":"Altman","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3E 0L8, Canada"},{"name":"Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Dean","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3E 0L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"ref_1","unstructured":"CCS (2023, December 01). Canadian Cancer Statistics. Available online: https:\/\/cancer.ca\/en\/cancer-information\/resources\/publications\/canadian-cancer-statistics-2023."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/ijc.34403","article-title":"Shifting incidence and survival of epithelial ovarian cancer (1995\u20132014): A SurvMark-2 study","volume":"152","author":"Cabasag","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_3","unstructured":"SEER (2018). Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.14336\/AD.2017.0607","article-title":"Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments","volume":"8","author":"Tortorella","year":"2017","journal-title":"Aging Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ygyno.2021.03.008","article-title":"Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer","volume":"161","author":"Mallen","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17588359231192397","DOI":"10.1177\/17588359231192397","article-title":"Ovarian cancer in the older patient: Where are we now? What to do next?","volume":"15","author":"Rousseau","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2010.09.010","article-title":"Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment","volume":"120","author":"Aletti","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2018.02.017","article-title":"Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis","volume":"149","author":"Schuurman","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaoncol.2021.0696","article-title":"Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO\/GCIG Randomized Clinical Trial","volume":"7","author":"Falandry","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.34350","article-title":"Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)","volume":"128","author":"Marth","year":"2022","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/IGC.0000000000001097","article-title":"Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index","volume":"27","author":"Ferrero","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11912-021-01097-9","article-title":"Determination of Biological Age: Geriatric Assessment vs Biological Biomarkers","volume":"23","author":"Diebel","year":"2021","journal-title":"Curr. Oncol. Rep."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/3\/102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:19Z","timestamp":1760105359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/3\/102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["curroncol31030102"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31030102","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}